Strainsforpains-EBYH, CEO Simon Shainberg Signs Strategic Product Commercialization Agreement with Cannabis Science; Shainberg’s 2024 Guidance Projects Strong Revenue Growth For Its Multiplied Cannabinoid Drug Commercialization Pipeline

NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Strainsforpains, Inc., fka/ E-Buy Home Inc., (OTC: EBYH) an emerging cannabinoid-based retail and wholesale drug commercialization specialist is very pleased to announce that it has just signed an international retail and wholesale cannabinoid drug commercialization agreement with Cannabis Science, Inc

Strainsforpains, Inc., President & CEO., Mr. Simon Shainberg stated, “Cannabis Science is best known for it’s Harvard Award Winning Cancer Killing Success. Cannabis Science has a robust pipeline of therapeutic and critical ailment cannabinoid drugs to be released. To start, Strainsforpains has successfully released a proven cannabinoid-based product pipeline and we have garnered excellent sales growth in a short period of time. The Cannabis Science CBN US Patent protected product pipeline is exciting for instant market penetration targeting sleep deprivation as well as targeting PTSD and other neurological conditions. The Harvard Award winning cancer killing success and the Cannabis Science Cancer drug pipeline is an automatic success magnet if you throw a little money at it to commercialize it through the FDA and other jurisdictional regulatory bodies to bring to market.”

CSi-CBN Patent:

“Composition for Treatment of Neurobehavioral Disorders” Protections and Product Release, Sleep, PTSD, Neurological Conditions. US Patent number US10413578. CBN Sleep Products for Sleep Deprivation, PTSD, OCD, ADHD and more. The Sleep deprivation and PTSD markets combined are well over $500 Billion Worldwide with a shortage of cost effect treatments and therapies. Leaving the opportunity to fulfill this demand a major windfall.

patents.google.com/patent/US10413578B2/en

Mr. Shainberg confirms again, “The introduction of diversified cannabinoid-based products, coupled with strategic partnerships with hemp farmers in Virginia and Pennsylvania, positions the company for rapid growth in 2024. We are proud to have established strong partnerships ensuring a resilient and optimized supply chain, with products stored both at our 7-acre Pennsylvania facility and our New York City locations. Has initial orders, comprising over 3000 units of CBD body cream, is set to be distributed across pharmacies and wellness centers in the Tri State area. Notable locations include Central Pharmacy of Brooklyn, DIV Pharmacy of Flatbush, Kyse Pharmacy of Rockaway, and other reputable dispensaries and health centers throughout New York.